Immunobiome Signs CDMO Agreement with BIOSE, a Global Leader in Microbiome Industry

[Asia Economy Reporter Hyunseok Yoo] Immunobiome, a microbiome therapeutic research and development company, announced on the 3rd that it has signed a CDMO (Contract Development and Manufacturing Organization) agreement with BIOSE, a global microbiome therapeutic CDMO specialist company.

BIOSE is a France-based microbiome therapeutic CDMO company and a world leader with 70 years of microbiome research experience. It researches live bacteria-based drugs called LBP (Live Biotherapeutic Products), conducting strain discovery, product development, clinical research, and manufacturing. BIOSE holds pharmaceutical GMP (Good Manufacturing Practice) certification for bacteria-based APIs (Active Pharmaceutical Ingredients) and the manufacturing of clinical and commercial products.

An Immunobiome official stated, “It is very meaningful that Immunobiome has signed a CDMO agreement with BIOSE, a world-leading company in the microbiome field, starting from our first pipeline.” He added, “Through this agreement, Immunobiome has been recognized by the global company BIOSE for its microbiome new drug development candidate derivation, activity-based quality verification, and elucidation of the mechanism of action, increasing the likelihood of successful new drug development. Additionally, we have secured a channel to stably supply raw materials for this purpose.” He continued, “We have completed mutual technology verification and plan to begin full-scale product manufacturing by the end of this year.”

Both Immunobiome and BIOSE plan to start full-scale product manufacturing from the end of this year, when BIOSE’s existing exclusive CDMO contract with the US company Evelo Biosciences expires. Evelo Biosciences is a Nasdaq-listed US company developing microbiome immuno-oncology drugs.

A company official emphasized, “Securing a company with excellent manufacturing facilities is the biggest bottleneck in microbiome therapeutic development.” He added, “Through this agreement, Immunobiome can accelerate preparations for full-scale clinical entry next year.”

This content was produced with the assistance of AI translation services.